Charles Schwab Investment Management Inc. Buys New Shares in Metsera Inc. $MTSR

Key Points

• Charles Schwab Investment Management Inc. has acquired a new position in Metsera Inc. with the purchase of 125,282 shares valued at approximately $3.41 million.
• Notable hedge funds such as Alphabet Inc. and Jennison Associates LLC also invested in Metsera during the first quarter, reflecting growing institutional interest.
• Analysts have given Metsera a consensus "Buy" rating, with a target price of $59.00, as several firms have adjusted their price objectives upwards recently.

Charles Schwab Investment Management Inc. acquired a new stake in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 125,282 shares of the company's stock, valued at approximately $3,410,000. Charles Schwab Investment Management Inc. owned about 0.12% of Metsera at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. acquired a new stake in Metsera during the first quarter valued at $39,932,000. TD Asset Management Inc acquired a new stake in Metsera during the first quarter valued at $2,091,000. Jennison Associates LLC acquired a new stake in Metsera during the first quarter valued at $9,679,000. Massachusetts Financial Services Co. MA acquired a new stake in Metsera during the first quarter valued at $13,111,000. Finally, Alphabet Inc. acquired a new stake in Metsera during the first quarter valued at $135,059,000.

Metsera Trading Up 1.8%

Shares of Metsera stock traded up $0.63 during trading on Thursday, reaching $36.29. The company's stock had a trading volume of 1,107,739 shares, compared to its average volume of 1,249,355. The business's fifty day moving average price is $34.58 and its 200-day moving average price is $28.65. Metsera Inc. has a one year low of $12.30 and a one year high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on MTSR shares. Guggenheim upped their price objective on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Bank of America upped their price objective on shares of Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Metsera in a report on Wednesday. Wall Street Zen upgraded shares of Metsera from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. Finally, Wells Fargo & Company started coverage on shares of Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $59.00.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.